Peptides for Alzheimer's Disease Research
About Alzheimer's Disease
Alzheimer's Disease (AD) is a neurodegenerative disorder that progressively damages brain cells, leading to memory loss, cognitive decline, and eventually death. Most commonly diagnosed after the age of 65, Alzheimer's also affects younger individuals, with about 5% of patients suffering from early-onset Alzheimer's Disease. Despite extensive research, the exact mechanisms causing Alzheimer's remain unclear. However, several hypotheses exist to explain its development.
One hypothesis focuses on the hyperphosphorylation of tau protein, while another centers around the buildup of amyloid plaques in the brain. These plaques are primarily composed of amyloid beta (Aβ) peptides, which are also implicated in other protein misfolding diseases, such as prion disorders. Understanding the role of peptides in Alzheimer's disease is critical to advancing potential treatments and therapies.
Role of Amyloid Beta Peptide in Alzheimer's Disease
Amyloid Beta (Aβ), also known as Beta Amyloid A4, plays a pivotal role in Alzheimer's disease pathology:
- Beta Amyloid A4 peptide (also referred to as Aβ, Abeta, Amyloid Beta) serves several functions in a healthy brain, such as activating kinases and regulating cholesterol transport.
- The accumulation of amyloid plaques, primarily composed of Aβ peptides, is a key pathological hallmark of Alzheimer's disease.
- Aβ peptides arise from the amyloid precursor protein (APP), undergoing proteolytic processing through β- and γ-secretases.
- These peptides vary in length (up to 43 amino acids), and certain isoforms, particularly Aβ(1-42) and Aβ(1-43), are highly prone to aggregation.
- A pathological increase in β/γ-secretase activities and a reduced clearance rate of Aβ peptides can result in their accumulation in the brain, contributing to the formation of toxic oligomers, fibrils, and plaques.
- These amyloid beta aggregates disturb the neuronal network and are believed to exert neurotoxic effects, leading to the cognitive and behavioral impairments observed in Alzheimer's patients.
- Despite years of research, the exact biochemical pathways driving the neurotoxic effects of Aβ peptides are still not fully understood, making Alzheimer's disease research a critical area of focus for peptide scientists.
JPT's Peptide Tools for Alzheimer's Research
Amyloid Beta Peptides for Alzheimer's Research
At JPT, we provide a comprehensive collection of Amyloid Beta (Aβ) peptides for studying Alzheimer's disease. Our peptide portfolio includes both various lengths of Aβ peptides and point-mutated versions of Aβ(1-42), known to be associated with familial forms of Alzheimer's. These peptides are delivered as HFIP-films (hexafluoroisopropanol) to eliminate unwanted secondary structures and any pre-existing oligomers or polymers, ensuring maximum experimental accuracy.
Researchers focusing on Alzheimer’s peptide studies can benefit from the high purity and customization of these peptides for in vitro and in vivo Alzheimer's research.
Custom Peptide Synthesis for Alzheimer's Disease Studies
Custom peptides synthesis for Alzheimer's play an essential role in advancing Alzheimer's studies by enabling scientists to create specific peptides for their unique research needs. JPT is renowned for our Custom Peptide Synthesis services, offering:
- Over 99% success rate in peptide synthesis, optimizing the process for each specific peptide sequence.
- Tailored solutions for Alzheimer's peptide research, with strict quality control and regulated processes to ensure consistency and accuracy.
- A dedicated team of peptide experts, ensuring your peptides meet the highest standards required for Alzheimer’s disease studies.
Whether you are looking for standard Aβ peptides or complex, modified peptides for Alzheimer's research, JPT’s synthesis services provide the best tools to accelerate your experiments.